A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers

NCT ID: NCT07277712

Last Updated: 2025-12-11

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 74 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-27
• Study Completion Date: 2026-09-30

Brief Summary

This study aims to evaluate the pharmacokinetic (PK) following administration of IN-M00002 tablet and co-administration of tegoprazan and naproxen, and to evaluate food-effect of IN-M00002 tablet in healthy adult volunteers

Detailed Description

A randomized, open-label, crossover study

[Part A] To evaluate and compare the pharmacokinetic and safety of co-administration of tegoprazan and naproxen versus administration of IN-M00002 tablet in healthy adult volunteers

[Part B] To evaluate the effects of food on the pharmacokinetic and safety of IN-M00002 tablet in healthy adult volunteers

Conditions

Healthy Volunteer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part B: Sequence 2 (Treatment D - Treatment C)

Period 1: Single dose of IN-M00002 tablet QD under fed conditions Period 2: Single dose of IN-M00002 tablet QD under fasted conditions

Group Type: EXPERIMENTAL

IN-M00002

Intervention Type: DRUG

IN-M00002 tablet QD

Part A: Sequence 1 (Treatment A - Treatment B)

Period 1: Single dose of tegoprazan 25 mg QD in combination with naproxen 500 mg BID Period 2: Single dose of IN-M00002 tablet BID

Group Type: EXPERIMENTAL

Tegoprazan

Intervention Type: DRUG

Tegoprazan 25 mg QD

Naproxen

Intervention Type: DRUG

Naproxen 500 mg BID

IN-M00002

Intervention Type: DRUG

IN-M00002 tablet BID

Part A: Sequence 2 (Treatment B - Treatment A)

Period 1: Single dose of IN-M00002 tablet BID Period 2: Single dose of tegoprazan 25 mg QD in combination with naproxen 500 mg BID

Group Type: EXPERIMENTAL

Tegoprazan

Intervention Type: DRUG

Tegoprazan 25 mg QD

Naproxen

Intervention Type: DRUG

Naproxen 500 mg BID

IN-M00002

Intervention Type: DRUG

IN-M00002 tablet BID

Part B: Sequence 1 (Treatment C - Treatment D)

Period 1: Single dose of IN-M00002 tablet QD under fasted conditions Period 2: Single dose of IN-M00002 tablet QD under fed conditions

Group Type: EXPERIMENTAL

IN-M00002

Intervention Type: DRUG

IN-M00002 tablet QD

Interventions

Tegoprazan

Tegoprazan 25 mg QD

Intervention Type: DRUG

Naproxen

Naproxen 500 mg BID

Intervention Type: DRUG

IN-M00002

IN-M00002 tablet QD

Intervention Type: DRUG

IN-M00002

IN-M00002 tablet BID

Intervention Type: DRUG

Other Intervention Names

K-CAB; Naxen-F

Eligibility Criteria

Inclusion Criteria

• Healthy adult aged ≥ 19 and ≤ 55 year-old at screening
• Body mass index (BMI) ≥ 19.0 kg/m2 and ≤ 27.0 kg/m2 with a body weight ≥ 45 kg at screening
• Those determined to be eligible for this study based on the findings of screening such as clinical laboratory tests (hematological test, blood chemistry test, blood coagulation test, urinalysis, test for viruses/bacteria, etc.), vital signs, and electrocardiogram (ECG) which are performed by the investigator according to the properties of medicines
• Those who have fully understood this clinical trial via detailed explanation, were willing to voluntarily participate in this study, and agreed to give written informed consent prior to the screening
• Those with a capability/willingness to participate throughout the study

Exclusion Criteria

• Medical history or evidence of clinically significant blood, renal, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological, musculoskeletal, oncological, or immune disease (except for history of simple dental treatment such as tartar, impacted teeth, and third molar teeth)
• Previous history of gastrointestinal disease (esophageal disease such as esophageal achalasia or esophageal stricture, inflammatory bowel disease (Crohn's disease, ulcerative colitis)) or surgery (except for simple appendectomy, hernia surgery, tooth extraction, etc.) which may affect drug absorption
• Sitting systolic blood pressure < 90 mmHg or ≥ 140 mmHg or diastolic blood pressure < 60 mmHg or ≥ 90 mmHg at screening
• Following findings of clinical laboratory tests:

• ALT or AST value > twice the upper limit of normal (ULN)
• History of periodic alcohol consumption exceeding 210 g/week within 6 months prior to screening (beer (5%) 1 glass (250 mL) = 10 g, soju (20%) 1 glass (50 mL) = 8 g, wine (12%) 1 glass (125 mL) = 12 g)
• Has taken any other investigational product within 6 months prior to the first dose of investigational product
• History of serious alcohol or drug misuse and abuse within 1 year prior to screening
• Administration of drugs known to markedly induce or inhibit drug metabolizing enzymes within 30 days prior to the first dose of the investigational product
• Daily use of ≥ 20 cigarettes within 6 months prior to screening
• Administration of a prescription or non-prescription drug within 10 days prior to the first dose of the investigational product
• Whole blood donation within 2 months prior to the first dose of the investigational product or apheresis donation within 1 month prior to the first dose of the investigational product
• Subjects who received a blood transfusion within 1 month prior to the first dose of the investigational product
• Those who may be put at an increased risk due to the administration of the investigational product and study participation or have a severe acute/chronic medical or mental condition which may interfere with the interpretation of study results
• Subjects with a history of hypersensitivity (e.g., asthma, rhinitis, nasal polyps, urticaria, or allergic reactions) to the components of tegoprazan or naproxen, benzimidazole derivatives, aspirin, or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors)
• Subjects currently receiving medications containing atazanavir, nelfinavir, or rilpivirine
• Women with a positive pregnancy test, pregnant, or breastfeeding
• Subjects are unable to use a highly effective method of contraception (e.g., correctly placed intrauterine device(IUD), sterilization surgery (vasectomy, tubal ligation, etc.))
• Subjects unable to consume a high-fat diet provided during Part B of the clinical trial
• Subjects who are considered ineligible to participate in this study at the discretion of the investigator

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

HK inno.N Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Seol Ju Moon, MD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Clinical Pharmacology Center, Jeonbuk National University Hospital

Locations

Jeonbuk National University Hospital

Jeonju, , South Korea

Countries

South Korea

Central Contacts

Seung Hee Jung, PhD

Role: CONTACT

shee.jung@inno-n.com

+82-31-5176-4653

Eun Ji Kim

Role: CONTACT

eunji.kim24@inno-n.com

+82-31-5176-4652

Facility Contacts

Seol Ju Moon, MD, PhD

Role: primary

sjmoon@jbcp.kr

+82-63-270-3087

Other Identifiers

IN_TNA_101

Identifier Type: -

Identifier Source: org_study_id